Rhythm Biosciences Seeks ASX Quotation for Additional Ordinary Shares

Rhythm Biosciences Ltd. ( (AU:RHY) ) has issued an update.

Rhythm Biosciences Ltd. has applied to the ASX for quotation of 61,901 new ordinary fully paid shares, which are being issued following the exercise or conversion of existing options or other convertible securities. The modest increase in quoted securities slightly expands the company’s issued capital base and may reflect ongoing shareholder participation in its equity incentive or financing structures.

While the volume of new shares is relatively small in the context of a listed company, the move formalizes their admission to trading on the ASX and maintains transparency around Rhythm Biosciences’ capital structure. This technical listing step ensures the newly issued securities become fully tradable on-market, providing liquidity to holders and marginally diluting existing shareholders.

The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.20 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.

More about Rhythm Biosciences Ltd.

Rhythm Biosciences Ltd. is an Australian-listed biotechnology company focused on developing diagnostic technologies, with its ordinary fully paid shares traded on the ASX under the ticker RHY. The company operates in the life sciences sector, targeting investors interested in healthcare and medical innovation opportunities.

Average Trading Volume: 993,151

Technical Sentiment Signal: Buy

Current Market Cap: A$69.21M

Find detailed analytics on RHY stock on TipRanks’ Stock Analysis page.